Efficacy and safety of calcineurin inhibitors compared with that of glucocorticoid for the treatment of atopic dermatitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17013807

Enrollment

Unknown

Registered

2017-12-10

Start date

2017-12-01

Completion date

Unknown

Last updated

2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Interventions

one:use topical creams:eloson

two:use topical creams:tacrolimus ointment 0.1%

Eligibility

Sex/Gender

All

Age

14 Years to 80 Years

Inclusion criteria

Inclusion criteria: Outpatients with atopic dermatitis at the age of 14-80 years.

Exclusion criteria

Exclusion criteria: 1. Who has serious uncontrolled chronic liver, kidney, heart, blood system, diabetes and lung disease. 2. History of malignant tumor; 3. Who has autoimmune disease or immunodeficiency disease; 4. Women who are pregnant, breast-feeding or using inappropriate contraception measures; 5. Can not be tested in accordance with the requirements of the program and follow up on time; 6. The researchers judged that it was not easy to take part in the cases of this study; 7. Involved other drug clinical researchers.

Design outcomes

Primary

Measure	Time frame
eczema area and severity index;	—

Secondary

Measure	Time frame
Body surface area;Self evaluation of pruritus;	—

Countries

China

Contacts

Public ContactDai Chunyang

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University

vel_rabbit@126.com+86 13681868832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026